Narcolepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Core Group:
- You have been diagnosed with Narcolepsy Type 1 or Type 2 (a sleep disorder causing excessive daytime sleepiness) according to recognised medical guidelines, and you were alive at any point during 2023 or 2024.
- You can be any age, ethnicity, or nationality.
- You are currently being treated or monitored at the study site and live within the hospital's local catchment area (those who have moved address or recently become adults may still be considered — confirm with trial site).
Supplementary Group:
- A specialist doctor has confirmed your diagnosis of Narcolepsy Type 1 or Type 2.
- You are 18 years old or older, OR you are the parent or guardian of a child under 18 who has been diagnosed with narcolepsy.
- You can be any gender, ethnicity, or nationality.
- You currently live in Spain.
Who may not be able to join:
Core Group:
- You have Narcolepsy Type 1 or Type 2 but do not live within the hospital's local catchment area.
Supplementary Group:
- You do not have a confirmed diagnosis of Narcolepsy Type 1 or Type 2 from a specialist doctor.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, Takeda
Phone: +1-877-825-3327
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Core Group: Prevalence of Participants With NT1 and NT2 per 100,000 Population; Core Group: Prevalence of Adult Participants With NT1 and NT2 per 100,000 Adult Population; Core Group: Prevalence of Paediatric/Adolescent Participants With NT1 and NT2 per 100,000 Paediatric/Adolescent Population; Core Group: Prevalence of Male Participants With NT1 and NT2 per 100,000 Male Population; Core Group: Prevalence of Female Participants With NT1 and NT2 per 100,000 Females Population; Core Group: Incidence of NT1 and NT2 per 100,000 Population; Core Group: Incidence of NT1 and NT2 per 100,000 Adult Pop...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.